Endophthalmitis is a rare but severe condition linked to ocular surgeries and trauma, it affects hundreds of thousands annually due to the high volume of surgeries, especially cataract procedures. This condition often results in irreversible retinal damage, leading to reduced vision and, in severe cases, vision loss. Moreover, current clinical options are inadequate for treating antimicrobial resistant (AMR) endophthalmitis. To overcome the limitations of current endophthalmitis therapy, we aim to develop a novel, injectable nanotherapeutic (Nanovision) to simultaneously address both AMR and retinal damage. Eradication of AMR bacteria will be accomplished by combining different types of antimicrobial materials to achieve highly efficient killing at low concentrations, ensuring minimal retinal toxicity and minimal usage of antibiotics. Additional retinal protection will be achieved by neutralizing ROS by natural flavonoids, distinguishing it from most existing nanodrugs containing immunosuppressive agents. This novel approach will significantly advance the treatment of postoperative endophthalmitis, particularly for cases involving AMR bacteria.